Cordycepin, a major compound separated from Cordyceps sinensis, is known as a potential novel candidate for cancer therapy. Breast cancer, the most typical cancer diagnosed among women, remains a global health problem. In this study, the anti-breast cancer property of cordycepin and its underlying mechanisms was investigated. The direct effects of cordycepin on breast cancer cells both in in vitro and in vivo experiments were evaluated. Cordycepin exerted cytotoxicity in MCF-7 and MDA-MB-231 cells confirmed by reduced cell viability, inhibition of cell proliferation, enhanced lactate dehydrogenase release and reactive oxygen species accumulation, induced mitochondrial dysfunction and nuclear apoptosis in human breast cancer cells. Cordycepin increased the activation of pro-apoptotic proteins, including caspase-8, caspase-9, caspase-3 and Bax, and suppressed the expression of the anti-apoptotic protein, B-cell lymphoma 2 (Bcl-2). The inhibition on MCF-7-xenografted tumor growth in nude mice further confirmed cordycepin's anti-breast cancer effect. These aforementioned results reveal that cordycepin induces apoptosis in human breast cancer cells via caspase-dependent pathways. The data shed light on the possibility of cordycepin being a safe agent for breast cancer treatment.
Breast cancer, the most typical cancer diagnosed among women [1] , remains a tough health problem worldwide. Although the mortality of breast cancer has been decreasing in North America and several European countries since the end of the 1980s [2] , several subtypes of breast cancer were found in patients. Each subtype exhibits varied responses to different therapeutic regimens, which limits the treatment options. In this scenario, it is imperative to explore different alternative therapies or medicines targeting one or more tumor-specific biomarkers that define the more aggressive breast carcinoma subtypes efficiently for improving treatment.
Cell shrinkage, chromatin condensation, and internucleosomal DNA fragmentation are always observed in cell apoptosis [3] . Extrinsic and intrinsic (mitochondrial) pathways related to caspase activation play important roles in cellular functions. On one hand, the increased cellular ROS production is responsible for the loss of the mitochondrial transmembrane potential (MMP; m). The increased permeability leads to the release of apoptosis factors including cytochrome c, which triggers the activation of caspase-9 [4] . On the other hand, caspase-8 can be triggered after the interaction of ligand with death receptors including Fas and tumor necrosis factor receptor (TNFR) [5] . Activated caspase-8 can cleave Bid into truncated Bid, which translocates to the mitochondria to initiate subsequently the mitochondrial apoptotic pathway. Following the activation of either caspase-8 or -9, the activation of caspase-3 is observed, which executes the death process by cleaving various substrates [6] .
Recently, various preventive and therapeutic agents against breast cancer have been found to be natural products [7] . Cordycepin, or 3'-deoxyadenosine, isolated from the parasitic fungus, Cordyceps sinensis, inhibits mRNA polyadenylation, platelet aggregation, cell proliferation and migration [8] . Several studies have confirmed that the anti-tumor property of cordycepin is mainly mediated by apoptosis. Previous in vitro study revealed that cordycepin effectively kills human breast cancer cells independently of estrogen receptor [9] . Moreover, cordycepin suppresses BRCA1deficient breast cancer cell proliferation and blocks lung injuryassociated inflammation via inhibiting poly ADP-ribose polymerase [10] . A recent study indicated that cordycepin reduces tumor formation in a metastatic model [11] . Furthermore, cordycepin successfully induces human breast epithelial cell apoptosis including MDA-MB-231 via DNA double strand breaks [12] . However, the underlying mechanism of cordycepin's anti-breast cancer activity is not clearly reported yet.
The anti-tumor effects of cordycepin on human breast cancer cells (MCF-7 and MDA-MB-231 cells) were investigated in our present research. The results revealed that cordycepin induced apoptotic cell death via caspase-dependent pathways. Additionally, cordycepin significantly suppressed MCF-7-xenografted tumor growth in nude mice with no decrease in mice bodyweight, which further confirmed its anti-tumor property.
Twenty-four hour cordycepin treatment at chosen doses significantly reduced cell viability in MCF-7 and MDA-MB-231 cells. The 24-h IC 50 values of cordycepin were 199 M in MCF-7 cells and 136 M in MDA-MB-231 cells ( Figure 1A ). After 24-h cordycepin (200 M) incubation, approximately 14% and 12% LDH over-release were observed in MCF-7 and MDA-MB-231 cells, respectively ( P<0.05; Figure 1B ). Cordycepin at doses of 50 M and 100 M strongly enhanced the apoptosis rate in breast cancer cells indicated by the increased blue fluorescence intensity of nuclear staining with Hoechst 33342 ( Figure 1C ). The effects of cordycepin on the ability of MCF-7 and MDA-MB-231 cells to form colonies were monitored for 7 days. The robust inhibitory activities of cordycepin were apparent at 25 M and 200 M cordycepin, when the clonogenic abilities of breast cancer cells were completely blocked ( Figure 1D ). Intracellular ROS has been emphasized in many previous studies due to its important role during mitochondrial apoptosis and cell death processes in general [13] . After exposure to 50 M and 100 M cordycepin for 12 h, a robust increment of intracellular ROS level was observed, exhibiting the potential role of ROS production inducing breast cancer cell damage ( Figure 2 ). Twelve-h cordycepin treatment significantly decreased MMP in MCF-7 and MDA-MB-231 cells, compared with non-treated cells. Cordycepin incubation at doses of 50 M and 100 M for 12 h strikingly decreased MMP evidenced by the reduction of the ratio of red to green fluorescence of JC-1 staining ( Figure 3A) . Additionally, the decrease in Bcl-2 level was sharp, but the increase in Bax expression reached a significant difference only at 50 M treatment in cordycepin-treated breast cancer cells ( Figure 3B ).
Western blot results revealed that cordycepin treatment strongly enhanced the activation of caspase-3, caspase-8 and caspase-9 in chosen breast cancer cells ( Figure 4 ). As indicated in the introduction section, these caspases are the critical elements of the extrinsic and intrinsic apoptotic pathways. As the second leading cause of cancer deaths among women worldwide, breast cancer continues to increase by approximately 2% per year [14] . Although surgery, chemotherapy and even radiation therapy have been applied to breast cancer, successful treatment has not been discovered yet [15] . Meanwhile, the cytotoxicity of anti-cancer agents to normal cells has been reported [16] , and natural compounds have gradually become one of the most productive strategies for anti-tumor agent development [17] . In the present study, the anti-breast cancer effects of cordycepin in both in vivo and in vitro models were investigated. Our present data reveal that cordycepin strongly induced apoptotic cell death via caspase-dependent mitochondrial and non-mitochondrial pathways, both in MCF-7 and MDA-MB-231 cells.
Cell apoptosis is an active physiological process resulting in cellular self-destruction. Besides biochemical changes, it is characterized by distinct morphological alterations, chromatin condensation, cell density increment, and the formation of apoptotic bodies [18] . In living organisms, the over-accumulation of ROS results in oxidative stress leading to cellular dysfunction and apoptosis [19] . Growing experimental data suggest that the increment of ROS is linked to the opening of the mitochondrial permeability transition pore and shows interaction between mitochondrial function [20] . Mitochondria are considered to be the main functional organelle for cancer chemopreventive agents [21] . The dissipation of MMP is used as an index for mitochondrial apoptosis which has been detected in our experiment [22] . During mitochondrial apoptosis, followed by MMP reduction, mitochondrial permeability transition pores (PTP) are opened, and further lead to pro-apoptotic molecules release; consequently, caspase-3 and PARP are activated [23] . Additionally, Bcl-2 family members, located in the outer mitochondrial membrane, contribute to the regulation of mitochondrial function [24] . Bcl-2 interacts with Bax, promoting the formation of Bcl-2/Bax heterodimer, which is responsible for MMP regulation [25] . Cordycepin simultaneously repressed Bcl-2 expression and up-regulated Bax level in breast cancer cells and in tumor tissues. Recently, a study shows that cordycepin induces SW480 and SW620 cell apoptosis by enhancing c-Jun N-terminal kinase and p38 mitogen-activated protein kinases activity and increasing the expression of Bcl-2 pro-apoptotic molecules [26] . Co-treatment with cordycepin and TRAIL induces Hep3B cells apoptosis related with the modulation of Bcl-2 family protein expression and the activation of the caspase cascade [27] . Altogether, it is suggested that cordycepin exerts an anti-breast cancer function via the activation of either the mitochondrial or intrinsic pathway of apoptosis [28] .
Caspases, synthesized as inactive pro-enzymes, proceed to be active parts via proteolytic cleavage, which are in charge of the disassembly of the cell into apoptotic bodies [29] . As reported, caspase-8 is considered to respond to extracellular apoptotic stimuli and can directly activate caspase-3 independently of the mitochondrial apoptotic pathway [30] . Moreover, cytochrome c released from mitochondria binds to apoptotic protease activating factor 1 (Apaf-1); the complex then recruits caspase-9, which activates the disassembly in response to agents or insults [31] . Consequently, via proteolytic cleavage, caspase-3 is activated by caspase-8 and caspase-9, and then cleaves vital cellular proteins or other caspases [32] . In other words, caspase-3 contributes to amplification of the caspase-8 and caspase-9 initiation signals, and plays a central role in the execution of the apoptotic program [33] . Our present data reveal that cordycepin possesses an anti-cancer effect by inducing apoptosis related to the regulation of caspase activations, which further target mitochondria and nuclei in MCF-7 and MDA-MB-231 cells.
Similar to the previous reports of natural cytotoxic compounds on tumors, our data indicate that cordycepin has multi-targets, not only mitochondria. Both death-receptor-and mitochondria-mediated pathways are involved in imperatorin mediated HepG2 cells apoptosis [34] . Baicalin inhibits HeLa cells proliferation via regulation of intracellular mitochondria and surface death receptors [35] . Interestingly, diosgenin causes HCC cell apoptosis by activating caspase-3, -8 and -9 without affecting Bcl-2 and Bax levels [36] . Several plausible molecular mechanisms can be applied to explain these phenomena. Ca 2+ , an important second messenger, is stored at high concentrations in the endoplasmic reticulum (ER) and is kept at very low levels in the cytoplasm and mitochondrial matrix [25] . In contrast, the elevated mitochondrial Ca 2+ concentration for a sustained period in turn triggers cell apoptosis. Our experiment successfully found that cordycepin induced Ca 2+ accumulation in cytoplasm of cancer cells. As reported, the over-expression of Bcl-2 contributes to reduced Ca 2+ transfer to the mitochondria during apoptotic stimulation [37] . Our present data at least partially confirm this conclusion. On the other hand, NADPH oxidase (Nox) -mediated production of ROS plays crucial roles in regulating apoptosis [38] . However, the relationship between the oxidative system, mitochondrial function and cordycepin-mediated cell damage still need further investigation.
In conclusion, our study demonstrated that cordycepin induced apoptotic cell death both in MCF-7 and MDA-MB-231 cells via caspase-dependent pathways, involve not only mitochondria but also the extrinsic apoptotic machinery. Cordycepin enhances caspase-8 activation and ROS accumulation which leads to apoptosis, indicated by the increment of the cleaved caspase-3 level. However, there are still several limitations in our present research. More data are required to confirm whether the pro-apoptosis effect of cordycepin relates to some upstream signaling transduction pathways such as MAPKs and Akt/PI 3. , supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin and 100 g/mL streptomycin under a humidified atmosphere containing 5% CO 2 and 95% air at 37C. The cultured medium was refreshed every 3 days. Cell culture reagents were obtained from Invitrogen, USA.
Experimental

MTT cell survival assay:
To test the effect of cordycepin (Sigma-Aldrich, USA) on cell viability, a quantitative colorimetric assay with 3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-di-phenytetrazoliumbromide (MTT) was applied. Cells (5,000 /100 mL) were plated into 96-well plates and incubated with cordycepin at doses of 12.5 M to 200 M for 24 h and 48 h. MTT (0.5 mg/mL) in phosphatebuffered saline (PBS) was added to each well, and the cells were incubated for 4 h at 37C in darkness. After aspirating the supernatant, 100 L DMSO was added to each well. The absorbance was then measured by a microplate reader at a wavelength of 540 nm (Bio-Rad, USA). Values of cell viability were expressed as a percentage of that from the corresponding control cells.
Released lactate dehydrogenase (LDH) analysis: MCF-7 and
MDA-MB-231 cells were seeded into 6-well plates at 5×10 4 per well, respectively. After 24-h cordycepin treatment, the cultured medium was collected and centrifuged at 1000 g for 5 min. Absorbance was spectrophotometrically measured at a wavelength of 490 nm according to LDH Assay Kit (Nanjing Jiancheng, China). LDH release was expressed as a percentage of that from corresponding control cells.
Cellular morphology analysis: Nucleus morphological alterations
were analyzed using Hoechst 33342 staining. MCF-7 and MDA-MB-231 cells were seeded into 6-well plates at 1 × 10 6 cells per well. After 24-h treatment with 50 µM and 100 µM cordycepin, cells were incubated with Hoechst 33342 (5 g/mL; Sigma-Aldrich, USA) for 15 min at 37°C in darkness. Following 3 washes with PBS, the changes in fluorescence intensity in the nucleus were photographed by a fluorescent microscope (20x; CCD camera, TE2000, Nikon, Japan).
Colony formation assays:
Crystal violet staining was performed to detect the colony formation. MCF-7 and MDA-MB-231 cells were seeded into 6-well plates at 5×10 4 cells per well. Fifty M and 100 M cordycepin was applied to treat cells for 7 days. A medium change containing either vehicle or cordycepin in complete medium was performed every 2 days. After treatment, cells were fixed in 75% methanol for 10 min at 4°C and stained with 1 mg/mL crystal violet for 30 min. After washing in PBS for at least 3 times, the cells were photographed.
Reactive oxygen species (ROS) detection:
The cellular ROS level was measured by the oxidant-sensing probe, dichlorodihydrofluorescein diacetate (DCFH-DA; Nanjing Jiancheng, China). After 12-h treatment, 10 M DCFH-DA dissolved in PBS was added to each well, and the cells were incubated at 37°C for 10 min. After 3 washes, the fluorescent color was photographed by a fluorescent microscope (20x; CCD camera, TE2000, Nikon, Japan). Detection of MMP: 5,5',6,6'-Tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1; Sigma-Aldrich, USA) is used to measure MMP changes. In normal respiring cells, the dye forms an aggregation in the mitochondrial membrane, exhibiting red fluorescence. When membrane potential is lost, monomeric JC-1 forms in the cytosol, exhibiting green fluorescence. Twelve-h treated cells were incubated with 2 M JC-1 at 37°C for 5 min in darkness. Following 3 washes with PBS, the changes of fluorescent color were examined using a fluorescent microscope (20x; CCD camera, TE2000, Nikon, Japan).
MCF-7-xenografted tumor model:
The experimental animal protocol was approved by the Animal Ethics Committee of Jilin University. The mice were housed in groups of 5 in cages and maintained on a 12 h light/dark cycle at 23 ± 1°C with water and food available ad libitum.
Tumors were generated by harvesting MCF-7 cells from mid-log phase cultures. A volume of 0.1 mL (1×10 8 cells/mL) of MCF-7 cell suspension was inoculated subcutaneously into the right flank of 6-week-old male BALB/c nude mice (purchased from Wei-tongli-hua Laboratory Animal Technology Co. Beijing China). Four days later, when the diameter of the tumors measured 2-3 mm, mice were divided into 2 groups (n=3 each) randomly. Mice were administered with 30 mg/kg of cordycepin (treated group) or double distilled (D.D.) water (vehicle group) orally every other day continuously for 2 weeks. Bodyweights and tumor dimensions were measured every other day. The equation of length × (width) 2 × 0.5 was applied to estimate the tumor volume (mm 3 ). At the end of the experiment, mice were sacrificed by 200 mg/kg pentobarbital injection. Tumor tissues were dissected from each mouse for Western blot analysis.
Western blot analysis: MCF-7 and MDA-MB-231 cells were planted into 6-well plates at 2 ×10 5 cells per well and treated with 50 M and 100 M cordycepin for 24 h. Cells and collected tumor Cordycepin as anti-breast cancer agent Natural Product Communications Vol. 11 (1) 2016 67 tissues were lysed by radioimmunoprecipitation assay (RIPA) buffer (Sigma-Aldrich, USA) containing a 1% protease inhibitor cocktail (Sigma-Aldrich, USA) and 2% phenylmethanesulfonyl fluoride (PMSF; Sigma-Aldrich, USA). Protein concentrations were determined using the Bio-Rad protein assay dye reagent. Equal amounts of the sample (40 μg) were separated via 10%-12% SDS-PAGE gel, and then electroblotted onto nitrocellulose membranes (0.45 m, Bio Basic, Inc). The transferred membranes were then incubated with the following primary antibodies at 4°C overnight at a dilution of 1 : 1000: B cell lymphoma-2 (Bcl-2), Bax, Cleaved caspase-9 (Abcam, UK), Cleaved caspase-3, Cleaved caspase-8, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Merck Millipore, Germany), followed by horseradish peroxidaseconjugated secondary antibody incubation (Santa Cruz, USA). Band detection was performed using the enhanced chemiluminescence (ECL) detection kits (GE Healthcare, UK). The intensity of the bands was quantified by software Image J.
Statistical analysis:
The values were analyzed by one-way analysis of variance (ANOVA) followed by Dunn's test using SPSS software (SPSS Inc., Chicago, IL, USA). The significance was chosen as P<0.05.
